Lung Cancer Clinical Trials in San Antonio

Showing 181-200 of 421 trials

Study of LP-184 in Patients With Advanced Solid Tumors

NCT05933265

The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184. Participants will receive LP-184 infusion during Day 1 and Day 8 of each 21-day cycle, for a minimum of two cycles. Patients will be monitored for safety, PK, and clinical activity

Advanced Solid TumorMetastatic Solid TumorGBM+4 more

Lantern Pharma Inc.175 participantsStarted Jun 2023

Springdale, Arkansas, United States • Los Alamitos, California, United States • Rolling Meadows, Illinois, United States +6 more locations

RECRUITINGPhase 1/2< 1 mile

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

NCT06090266

This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subjects with advanced solid tumors.

CancerTumor, SolidMalignant Neoplasm+4 more

OncoResponse, Inc.168 participantsStarted Oct 2023

Austin, Texas, United States • Irving, Texas, United States • San Antonio, Texas, United States +1 more locations

Study of LP-184 in Patients With Advanced Solid Tumors

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Lung Cancer Trials in Other Cities

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Avelumab in First-line NSCLC (JAVELIN Lung 100)

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

Other Conditions in San Antonio